Neuropathy & Nerve Health — Peptide Research Overview

Relevant Compounds

• Cerebrolysin — Porcine brain-derived peptide mixture with BDNF-like, CNTF-like, and IGF-like activity. Used clinically for stroke, traumatic brain injury, and Alzheimer's disease in Europe and Asia.
• BPC-157 — Shown to promote peripheral nerve regeneration and protect against neurotoxin-induced damage in animal models.

What the Research Shows

Cerebrolysin

[Human Trial] Cerebrolysin is registered as a drug in over 50 countries and has been evaluated in multiple RCTs for stroke recovery, Alzheimer's disease, and traumatic brain injury. The CASTA trial (ischemic stroke) showed improved neurological outcomes at day 90 in patients receiving Cerebrolysin vs. placebo, particularly in those with severe strokes. A Cochrane review acknowledges the positive trial data while noting methodological heterogeneity. The proposed mechanism involves a mixture of low-molecular-weight neuropeptides (BDNF, CNTF, GDNF mimetics) that promote neuronal survival, axonal sprouting, and synaptic plasticity. Peripheral neuropathy applications are less studied but biologically plausible given the neurotrophic mechanism.

BPC-157

[Animal Study] BPC-157 has demonstrated nerve repair activity in rodent models of sciatic nerve crush injury — one of the standard models for peripheral neuropathy research. Treated animals show faster recovery of paw withdrawal reflexes, improved nerve conduction velocities, and histological evidence of remyelination. BPC-157 also protects against neurotoxin-induced dopaminergic neuron damage, suggesting broader neuroprotective activity beyond peripheral nerve repair.

Evidence Summary